Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: A reveal registry analysis

Chest

Volumn 144, Issue 1, 2013, Pages 169-176

  Poms, Abby D ^a   Turner, Michelle ^b   Farber, Harrison W ^c   Meltzer, Leslie A ^d   McGoon, Michael D ^e  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ICON Late Phase and Outcomes Research   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Actelion Pharmaceuticals US Inc   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DEATH; DEPRESSION; DISEASE REGISTRY; EXERCISE TEST; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; SLEEP DISORDERED BREATHING; SURVIVAL; THYROID DISEASE;

EID: 84880073595     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-3241     Document Type: Article

References (24)

1. McGoon MD, Krichman A, Farber HW, et al. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008; 83 (8): 923-931.
2. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009; 54 (suppl 1): S43-S54.
3. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54 (suppl 1): S55-S66.
4. Le Pavec J, Souza R, Herve P, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med. 2008; 178 (6): 637-643.
5. Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008; 8 (11): 2445-2453.
6. McLaughlin VV, Presberg KW, Doyle RL, et al; American College of Chest Physicians. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004; 126 (1)( suppl): 78S - 92S.
7. Krowka MJ, Miller DP, Barst RJ, et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest. 2012; 141 (4): 906-915.
8. Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012; 141 (2): 354-362.
9. Naqvi K, Garcia-Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol. 2011; 29 (16): 2240-2246.
10. Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst. 2011; 103 (14): 1101-1111.
11. Crisafulli E, Gorgone P, Vagaggini B, et al. Efficacy of standard rehabilitation in COPD outpatients with comorbidities. Eur Respir J. 2010; 36 (5): 1042-1048.
12. Terzano C, Conti V, Di Stefano F, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung. 2010; 188 (4): 321-329.
13. Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos G. Comorbidity in patients with rheumatoid arthritis: effect on health-related quality of life. J Rheumatol. 2004; 31 (1): 58-65.
14. Coghlan JG, Pope J, Denton CP. Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. Curr Opin Pulm Med. 2010; 16 (suppl 1): S27-S34.
15. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. National Institutes of Health. Obes Res. 1998; 6 (suppl 2): 51S - 209S.
16. US National Institutes of Health. A multicenter, double-blind, placebo-controlled phase 3 study to demonstrate the efficacy and safety of ACT-293987 in patients with pulmonary arterial hypertension. NCT01106014. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2010. http://clinicaltrials. gov/show/NCT01106014. Updated October 8, 2012.
17. US National Institutes of Health. Long-term single-arm openlabel extension study of the SERAPHIN Study, to assess the safety and tolerability of ACT 064992 in patients with symptomatic pulmonary arterial hypertension. NCT00667823. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2008. http://clinicaltrials.gov/ct2/show/NCT006678230. Updated October 23, 2012.
18. US National Institutes of Health. A 16-week, international, multicenter, double-blind, randomized, placebo-controlled comparison of the efficacy and safety of oral UT-15C sustained release tablets in combination with an endothelin receptor antagonist and/or a phosphodiesterase-5 inhibitor in subjects with pulmonary arterial hypertension. NCT00325442. ClinicalTrials.gov. Bethesda, MD: National Institutes of Health; 2006. http://clinicaltrials.gov/ ct2/show/NCT00325442. Updated January 18, 2012.
19. Burger CD, Foreman AJ, Miller DP, Safford RE, McGoon MD, Badesch DB. Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the Regis try to Evaluate Early and Long-term PAH Disease Management with normative values from the National Health and Nutrition Examination Survey. Mayo Clin Proc. 2011; 86 (2): 105-112.
20. Le-Bert G, Santana O, Pineda AM, Zamora C, Lamas GA, Lamelas J. The obesity paradox in elderly obese patients undergoing coronary artery bypass surgery. Interact Cardiovasc Thorac Surg. 2011; 13 (2): 124-127.
21. Kim BJ, Lee SH, Ryu WS, Kim CK, Lee J, Yoon BW. Paradoxical longevity in obese patients with intracerebral hemorrhage. Neurology. 2011; 76 (6): 567-573.
22. Vemmos K, Ntaios G, Spengos K, et al. Association between obesity and mortality after acute first-ever stroke: the obesitystroke paradox. Stroke. 2011; 42 (1): 30-36.
23. Markart P, Ghofrani HA, Grimminger F, Günther A. Pulmonary hypertension in COPD and interstitial lung diseases [in German]. Dtsch Med Wochenschr. 2009; 134 (suppl 5): S164-S166.
24. Lowe BS, Therrien J, Ionescu-Ittu R, Pilote L, Martucci G, Marelli AJ. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol. 2011; 58 (5): 538-546.